A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
A phase 2 trial of Pembrolizumab and Dostarlimab in non-small-cell lung cancer, run by GlaxoSmithKline, active and no longer recruiting.
Overview
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer is a phase 2 interventional study registered as NCT05565378 by GlaxoSmithKline, with 351 participants enrolled, started 2022-10-14 and due to reach its primary completion in 2026-11-09. Interventions recorded: Pembrolizumab, Dostarlimab, Belrestotug and Nelistotug.
Similar pages
not linked directly; found by shared links- TrialA Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
Shares Dostarlimab, GSK, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Shares Dostarlimab, GSK and the tag pipeline.